HPTN INVESTIGATOR MEETING

Wafaa El-Sadr, MD, MPH, MPA
Welcome to the New HPTN
The HIV Prevention Trials Network (HPTN) is committed to advancing HIV prevention through the use of integrated strategies, centered on the goal of reducing HIV incidence in populations at greatest risk for infection.
Network Structure

Leadership and Operations Center

N. Sista

Network Oversight Committees

Science Review
S. Vermund

Study Monitoring
J. Hughes

Manuscript Review
T. Coates

Performance Evaluation
Q. Abdool Karim

Scientific Committees

Adolescents at Risk
Women at Risk
Substance Users
MSM SC
Integrated Strategies

Executive Committee

D. Serwadda
S. Vermund / Q. Abdool Karim
Sista/ Eshleman/Donnell/Turner
Newton Kumwenda
Steve Shoptaw
2 NIH Representatives

Scientific Advisory Group (SAG)
PrEP External Advisory Committee (PEAC)

Working Groups

Community
J. Frohlich / M. Turner
Ethics
J. Sugarman / J. Singh

Laboratory Center

S. Eshleman

Statistical and Data Management Center

D. Donnell
<table>
<thead>
<tr>
<th>Adolescents at Risk</th>
<th>Women at Risk</th>
<th>Substance Use</th>
<th>MSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audrey Pettifor</td>
<td>Ada Adimora</td>
<td>Steffanie Strathdee</td>
<td>Ken Mayer</td>
</tr>
<tr>
<td>Frances Cowan</td>
<td>Elizabeth Bukusi</td>
<td>Nabila El-Bassel</td>
<td>Darrell Wheeler</td>
</tr>
<tr>
<td>Sarah Dlamini</td>
<td>Sevgi Aral</td>
<td>Apinun Aramrattana</td>
<td>Chris Beyrer</td>
</tr>
<tr>
<td>Linda-Gail Bekker</td>
<td>Judy Auerbach</td>
<td>Raquel de Boni</td>
<td>Beatriz Grinsztejn</td>
</tr>
<tr>
<td>Sybil Hosek</td>
<td>Gina Brown</td>
<td>Pedro Gonzales</td>
<td>Tim Holtz</td>
</tr>
<tr>
<td>Sophia Hussein</td>
<td>Sally Hodder</td>
<td>Adeeba Kamarulzaman</td>
<td>Bob Remien</td>
</tr>
<tr>
<td></td>
<td>Angela Kashuba</td>
<td>Irene Kuo</td>
<td>Jorge Sanchez</td>
</tr>
<tr>
<td></td>
<td>Nelly Mugo</td>
<td>David Metzger</td>
<td>Theo Sandfort</td>
</tr>
<tr>
<td></td>
<td>Chitra Singh</td>
<td>Vu Minh Quan</td>
<td>Patrick Sullivan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Integrated Strategies</th>
<th>Ethics</th>
<th>Community</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connie Celum</td>
<td>Jeremy Sugarman</td>
<td>Janet Frohlich</td>
</tr>
<tr>
<td>Susan Buchbinder</td>
<td>Jerome Singh</td>
<td>Melissa Turner</td>
</tr>
<tr>
<td>Peter Cherutich</td>
<td>Mark Barnes</td>
<td>Charles Chasakara</td>
</tr>
<tr>
<td>Sinead Delaney-Moretlwe</td>
<td>Anant Bhan</td>
<td>Shipeng Chen</td>
</tr>
<tr>
<td>Tim Hallett</td>
<td>David Borasky</td>
<td>David Galetta</td>
</tr>
<tr>
<td>Mina Hosseinipour</td>
<td>Yali Cong</td>
<td>Daniel Gondwe</td>
</tr>
<tr>
<td>Risha Irvin</td>
<td>Vanessa El-Harar</td>
<td>Craig Hutchinson</td>
</tr>
<tr>
<td>Heidi Van Rooyen</td>
<td>Robert Klitzman</td>
<td>Ernest Moseki</td>
</tr>
<tr>
<td>Valdilea Veloso</td>
<td>Alex London</td>
<td>Agnes Nondo</td>
</tr>
<tr>
<td></td>
<td>Florence Luna</td>
<td>Fatima Zulu</td>
</tr>
<tr>
<td></td>
<td>Kate MacQueen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Wakefield</td>
<td></td>
</tr>
</tbody>
</table>
Where are HPTN sites located?

★ Funded HPTN CRS  ★ Protocol Specific Sites
Ultimate Goal for the HPTN Research Agenda

Identify integrated strategies for prevention of HIV transmission with the following attributes:

• Reduce HIV incidence by >50%
• Are tailored to populations at risk
• Are safe, acceptable and feasible
• Are cost effective
• Are scalable
• Are adaptive to future prevention methods
Integrated Strategies

**HIV-INFECTED**
- **Behavioral**
  - Maximize ART Effectiveness
- **ART**
- **Structural**
- **Biomedical**

**HIV-UNINFECTED**
- **Behavioral**
  - Maximize PrEP Effectiveness
- **PrEP**
- **Structural**
- **Biomedical**

**Vanguard Studies, if needed**
- Mathematical Modeling

**Integrated Strategy Trials**

**Reduce HIV incidence**

**PUBLIC HEALTH IMPACT**

**POPULATIONS**
- Young Women,
- MSM,
- PWID

**Evaluate new PrEP Drugs**
Vanguard to Phase 3 Efficacy Studies

Vanguard Study

- Recruit and retain population
- Uptake
- Adherence, persistence

Go/ No Go

- Information from other studies
- Modeling research

Phase 3 Integrated Strategy Efficacy Study
Pre-exposure Prophylaxis (PrEP)

Two Goals

1. Optimize effectiveness of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)

2. Develop novel agents/regimes for PrEP
Proposed Integrated Strategy Research Agenda

Priority Populations

- MSM in the Americas
- Young women in Southern Africa
- Persons who inject drugs (PWID) in Eastern Europe and Asia
Purpose of this meeting

- Overview of new HPTN
- Network structure
- Network processes
- Engagement of investigators